



Supplementary Figure S1



Supplementary Figure S1. CA-treatment of chronic EAE, starting at peak of disease. Clinical EAE scores comparing vehicle controls to CA-treatment when treatment has been started at the peak of disease. No difference could be seen between vehicle control and CA-treated group. Means \pm SEM are shown from one representative of two independent experiments (n = 10 females per group).


Supplementary Figure S2



Supplementary Figure S2. AT1R inhibition attenuates antigen-specific T cell activation.

Recall proliferation of MOG35-55 restimulated lymphocytes from immunized WT vehicle controls, WT CA-treated, and AT1R^{-/-} vehicle-treated mice. CA-treatment and knockout of AT1Ra reduces proliferation of T cells. Representative data is shown for one of two independent experiments, each carried out in triplicates. * p < 0.01, ** p < 0.001 (Student's t-test).

Supplementary Figure S3



Supplementary Figure S3. Up-regulation of AT1R expression during EAE. C57BL/6 mice were immunized with MOG₃₅₋₅₅ and adjuvants. Sagittal brain sections from naïve mice or EAE mice sacrificed at days 7, 14 or 21 post immunization were immunostained for AT1R and images were taken from the cerebellum. Right panel shows boxed region at higher magnification. Scale bars = 200 μ m (left panel), 50 μ m (right panel).